单剂量0.15%酒石酸溴莫尼定对正常个体脉络膜厚度的影响（英文）

The effect of single dose of brimonidine-purite 0.15% on choroidal thickness in healthy volunteers

目的:通过使用频域相干光学断层深度增强成像测量正常个体脉络膜厚度(CT)以评估眼部使用0.15%酒石酸溴莫尼定对眼后节的潜在影响。方法:前瞻性、安慰剂对照干预性临床试验,包括32例32眼正常个体。第1d,受试者接受一滴无防腐剂人工泪液作为安慰剂;第2d,接受一滴0.15%酒石酸溴莫尼定。收集每次用药前及用药后1、3和5h,眼压,眼灌注压(OPP)以及EDI-SD-OCT数据。结果:相较于最初测量结果,局部应用0.15%酒石酸溴莫尼定后,在下凹(P=0.001),颞凹1500μm处(P=0.003),鼻凹1500μm处(P=0.003)测得脉络膜厚度显著增加。整个研究过程中,安慰剂组脉络膜厚度未发生变化(P>0.05)。分别使用安慰剂和溴莫尼定后眼灌注压没有显著降低(P>0.05)。研究中未观察到不良反应。结论:与预期相悖,局部应用0.15%酒石酸溴莫尼定导致下凹、颞凹、鼻凹处脉络膜厚度增加。

AIM ： To evaluate the potential posterior segment effects of topical application of brimonidine- purite 0. 15% through measurement of choroidal thickness （CT） in healthy eyes using enhanced depth imaging spectral- domain optical coherence tomography （EDI-SD-OCT）. METHODS： Thirty-two eyes of 32 healthy subjects were included in this prospective, placebo - controlled interventional clinical trial. They received one drop of topical preservative-free artificial tears as placebo for the first day and one drop of brimonidinepurite 0.15% for the second day. Intraocular pressure, ocular perfusion pressure （ OPP）, and EDI - SD- OCT were performed at baseline, at 1, 3 and 5h after the treatments. RESULTS： Compared to the measurements obtained at baseline, the CT measurements obtained after the topical application of brimonidinepurite 0. 15% significantly increased at the sub-fovea （ P= 0. 001 ）, at temporal 1500 μm to the fovea （P=0.003） and at nasal 1500 μm to the fovea （P=0. 003）. Choroidal thickness was unchanged in placebo group during the study （P 〉0.05）. There was no significant reduction in the OPP in both groups （P 〉0.05）. There were no adverse events during the study. CONCLUSIONS： Contrary to expectations, topical administration of brimonidine-purite 0.15% resulted with thickening of sub-foveal, might be related to altered in choroidal vessels. temporal and nasal CT. This auto- regulation mechanismsin choroidal vessels.